Canada markets close in 3 hours 23 minutes

RenovoRx, Inc. (RNXT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2100-0.0100 (-0.82%)
As of 11:45AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.2200
Open1.1900
Bid0.8352 x 200
Ask1.5400 x 200
Day's Range1.1900 - 1.2100
52 Week Range0.5310 - 3.2900
Volume984
Avg. Volume49,872
Market Cap28.979M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement

    LOS ALTOS, Calif., April 18, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising activity, it has received written confirmation from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq L

  • Business Wire

    RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

    LOS ALTOS, Calif., April 16, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah. Clinical data was presented by David Sperling, MD, Associate Professor of Radi

  • Business Wire

    RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

    LOS ALTOS, Calif., April 15, 2024--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.